Overview Testosterone Treatment for Multiple Sclerosis Status: Completed Trial end date: 2007-03-01 Target enrollment: Participant gender: Summary Since men are less likely to develop multiple sclerosis, the hypothesis was that testosterone might be protective in MS. Men with MS for followed untreated for 6 months, followed by a 12 month treatment period with Androgel. Phase: Phase 1/Phase 2 Details Lead Sponsor: University of California, Los AngelesCollaborator: National Multiple Sclerosis SocietyTreatments: MethyltestosteroneTestosteroneTestosterone 17 beta-cypionateTestosterone enanthateTestosterone undecanoate